Literature DB >> 22293431

Spontaneous clearance of chronic hepatitis C virus infection is associated with appearance of neutralizing antibodies and reversal of T-cell exhaustion.

Sukanya Raghuraman1, Heiyoung Park, William O Osburn, Emily Winkelstein, Brian R Edlin, Barbara Rehermann.   

Abstract

BACKGROUND: Hepatitis C virus (HCV) readily establishes chronic infection with exhaustion of HCV-specific T cells and escape from neutralizing antibodies. Spontaneous recovery from chronic infection is rare and has never to our knowledge been studied immunologically.
METHODS: We prospectively studied, from prior to infection through >2 years of follow-up, cytokines, HCV-specific T cells, and antibodies, as well as viral sequence evolution in a white male who spontaneously cleared HCV genotype 1a after 65 weeks.
RESULTS: Significant alanine aminotransferase and plasma cytokine elevation and broad HCV-specific T-cell responses did not result in HCV clearance in the acute phase. Frequency and effector function of HCV-specific T cells decreased thereafter, and HCV titers stabilized as is typical for the chronic phase. HCV clearance after 65 weeks followed the appearance of neutralizing antibodies at week 48 and was associated with reversal of HCV-specific T-cell exhaustion, as evidenced by reduced programmed death-1 (PD-1) expression and improved T-cell function. Clearance occurred without inflammation or superinfection with hepatitis B virus, human cytomegalovirus virus, influenza, and Epstein-Barr virus.
CONCLUSIONS: T-cell exhaustion is reversible at least in the first 2 years of chronic HCV infection, and this reversion in conjunction with neutralizing antibodies may clear HCV. These findings are relevant for immunotherapy of chronic infections.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22293431      PMCID: PMC3274373          DOI: 10.1093/infdis/jir835

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  49 in total

1.  Cross-reactivity between hepatitis C virus and Influenza A virus determinant-specific cytotoxic T cells.

Authors:  H Wedemeyer; E Mizukoshi; A R Davis; J R Bennink; B Rehermann
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

2.  Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy.

Authors:  C Boni; A Penna; G S Ogg; A Bertoletti; M Pilli; C Cavallo; A Cavalli; S Urbani; R Boehme; R Panebianco; F Fiaccadori; C Ferrari
Journal:  Hepatology       Date:  2001-04       Impact factor: 17.425

3.  Compensatory mutations in E1, p7, NS2, and NS3 enhance yields of cell culture-infectious intergenotypic chimeric hepatitis C virus.

Authors:  MinKyung Yi; Yinghong Ma; Jeremy Yates; Stanley M Lemon
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

4.  Spontaneous elimination of serum hepatitis C virus (HCV) RNA in chronic HCV carriers: a population-based cohort study.

Authors:  Hisayoshi Watanabe; Takafumi Saito; Haruhide Shinzawa; Kazuo Okumoto; Etsuko Hattori; Tohru Adachi; Tadashi Takeda; Kazuhiko Sugahara; Jun-itsu Ito; Koji Saito; Hitoshi Togashi; Ryosuke Suzuki; Masahiro Hayashi; Tatsuo Miyamura; Yoshiharu Matsuura; Sumio Kawata
Journal:  J Med Virol       Date:  2003-09       Impact factor: 2.327

5.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

Authors:  Michael W Fried; Mitchell L Shiffman; K Rajender Reddy; Coleman Smith; George Marinos; Fernando L Gonçales; Dieter Häussinger; Moises Diago; Giampiero Carosi; Daniel Dhumeaux; Antonio Craxi; Amy Lin; Joseph Hoffman; Jian Yu
Journal:  N Engl J Med       Date:  2002-09-26       Impact factor: 91.245

6.  Hepatitis C virus eradication associated with hepatitis B virus superinfection and development of a hepatitis B virus specific T cell response.

Authors:  Norbert H Gruener; Maria-Christina Jung; Axel Ulsenheimer; Tilman J Gerlach; Helmut M Diepolder; Carl A Schirren; Robert Hoffmann; Martin Wächtler; Markus Backmund; Gerd R Pape
Journal:  J Hepatol       Date:  2002-12       Impact factor: 25.083

Review 7.  No one is naive: the significance of heterologous T-cell immunity.

Authors:  Raymond M Welsh; Liisa K Selin
Journal:  Nat Rev Immunol       Date:  2002-06       Impact factor: 53.106

8.  Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles.

Authors:  Mayla Hsu; Jie Zhang; Mike Flint; Carine Logvinoff; Cecilia Cheng-Mayer; Charles M Rice; Jane A McKeating
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-21       Impact factor: 11.205

9.  Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection.

Authors:  Heiner Wedemeyer; Xiao-Song He; Michelina Nascimbeni; Anthony R Davis; Harry B Greenberg; Jay H Hoofnagle; T Jake Liang; Harvey Alter; Barbara Rehermann
Journal:  J Immunol       Date:  2002-09-15       Impact factor: 5.422

10.  Determinants of viral clearance and persistence during acute hepatitis C virus infection.

Authors:  R Thimme; D Oldach; K M Chang; C Steiger; S C Ray; F V Chisari
Journal:  J Exp Med       Date:  2001-11-19       Impact factor: 14.307

View more
  73 in total

1.  Spontaneous clearance of hepatitis C virus during alcoholic hepatitis: the alcohol killed the virus?

Authors:  Mário Jorge Silva; Filipe Calinas
Journal:  BMJ Case Rep       Date:  2015-10-19

2.  The Impact of IFN-γ Gene Polymorphisms on Spontaneous Clearance of HCV Infection in Fars Province, Southern of Iran.

Authors:  Jamal Sarvari; Afagh Moattari; Neda Pirbonyeh; Maryam Moini; Seyed Younes Hosseini
Journal:  J Clin Lab Anal       Date:  2015-05-20       Impact factor: 2.352

3.  Protective cellular immune response against hepatitis C virus elicited by chimeric protein formulations in BALB/c mice.

Authors:  Santa Olivera; Angel Perez; Viviana Falcon; Dioslaida Urquiza; Dagmara Pichardo; Gillian Martinez-Donato
Journal:  Arch Virol       Date:  2020-02-03       Impact factor: 2.574

Review 4.  The Strange, Expanding World of Animal Hepaciviruses.

Authors:  Alex S Hartlage; John M Cullen; Amit Kapoor
Journal:  Annu Rev Virol       Date:  2016-09-29       Impact factor: 10.431

5.  CD4+ T-Cell-Dependent Reduction in Hepatitis C Virus-Specific Neutralizing Antibody Responses After Coinfection With Human Immunodeficiency Virus.

Authors:  Justin R Bailey; Kimberly A Dowd; Anna E Snider; William O Osburn; Shruti H Mehta; Gregory D Kirk; David L Thomas; Stuart C Ray
Journal:  J Infect Dis       Date:  2015-03-09       Impact factor: 5.226

6.  Hepatic IFN-Induced Protein with Tetratricopeptide Repeats Regulation of HCV Infection.

Authors:  Yuji Ishida; Masakazu Kakuni; Bo-Ram Bang; Go Sugahara; Daryl T-Y Lau; Chise Tateno-Mukaidani; Meng Li; Michael Gale; Takeshi Saito
Journal:  J Interferon Cytokine Res       Date:  2019-03       Impact factor: 2.607

7.  Novel E2 Glycoprotein Tetramer Detects Hepatitis C Virus-Specific Memory B Cells.

Authors:  Maude Boisvert; Wanrui Zhang; Elizabeth J Elrod; Nicole F Bernard; Jean-Pierre Villeneuve; Julie Bruneau; Joseph Marcotrigiano; Naglaa H Shoukry; Arash Grakoui
Journal:  J Immunol       Date:  2016-11-14       Impact factor: 5.422

Review 8.  Current progress in development of hepatitis C virus vaccines.

Authors:  T Jake Liang
Journal:  Nat Med       Date:  2013-07       Impact factor: 53.440

9.  The frequency of CD127(+) hepatitis C virus (HCV)-specific T cells but not the expression of exhaustion markers predicts the outcome of acute HCV infection.

Authors:  Eui-Cheol Shin; Su-Hyung Park; Michelina Nascimbeni; Marian Major; Laura Caggiari; Valli de Re; Stephen M Feinstone; Charles M Rice; Barbara Rehermann
Journal:  J Virol       Date:  2013-02-06       Impact factor: 5.103

10.  Clearance of hepatitis C infection is associated with the early appearance of broad neutralizing antibody responses.

Authors:  William O Osburn; Anna E Snider; Brittany L Wells; Rachel Latanich; Justin R Bailey; David L Thomas; Andrea L Cox; Stuart C Ray
Journal:  Hepatology       Date:  2014-04-29       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.